Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system.

Kosse LJ, Jessurun NT, Hebing RCF, Huiskes VJB, Spijkers KM, van den Bemt BJF, Nurmohamed MT.

Rheumatology (Oxford). 2019 Sep 30. pii: kez412. doi: 10.1093/rheumatology/kez412. [Epub ahead of print]

PMID:
31566226
2.

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.

de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.

Arthritis Res Ther. 2019 Sep 14;21(1):208. doi: 10.1186/s13075-019-1998-4.

3.

The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.

Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T.

Clin Exp Rheumatol. 2019 Aug 30. [Epub ahead of print]

PMID:
31498069
4.

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence.

van Heuckelum M, Linn AJ, Vandeberg L, Hebing RCF, van Dijk L, Vervloet M, Flendrie M, Nurmohamed MT, van Dulmen S, van den Bemt BJF, van den Ende CHM.

PLoS One. 2019 Aug 30;14(8):e0221290. doi: 10.1371/journal.pone.0221290. eCollection 2019.

5.

Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro et al.

Agca R, Heslinga SC, Rollefstad S, Heslinga S, Södergren A, Semb AG, Kitas GD, Sattar N, Nurmohamed MT; EULAR task force “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update”.

Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215748. doi: 10.1136/annrheumdis-2019-215748. [Epub ahead of print] No abstract available.

PMID:
31413003
6.

Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme.

Heslinga M, Van Den Oever I, Jonker DL, Griep EN, Griep-Wentink H, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters M, Van Schaardenburg D, Nurmohamed MT.

Scand J Rheumatol. 2019 Jun 18:1-8. doi: 10.1080/03009742.2019.1600718. [Epub ahead of print]

PMID:
31210083
7.

Methotrexate for Prevention of Cardiovascular Events.

van Vollenhoven RF, Nurmohamed M.

N Engl J Med. 2019 Jun 6;380(23):2276-2277. doi: 10.1056/NEJMc1905061. No abstract available.

PMID:
31167066
8.

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.

Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R.

Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930.

9.

Cardiovascular Event Risk in Rheumatoid Arthritis is Higher than in Type 2 Diabetes: a 15 Year Longitudinal Study.

Agca R, Hopman LHGA, Laan KCJ, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, Nurmohamed MT.

J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print]

PMID:
31092721
10.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print] No abstract available.

PMID:
31072816
11.

Can personalized use of NSAIDs be a reality in the clinic?

Nurmohamed MT.

Nat Rev Rheumatol. 2019 Jul;15(7):387-388. doi: 10.1038/s41584-019-0225-7. No abstract available.

PMID:
31040441
12.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26.

PMID:
31028551
13.

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.

L' Ami MJ, Ruwaard J, Krieckaert C, Nurmohamed MT, van Vollenhoven RF, Rispens T, Wolbink GJ.

Scand J Rheumatol. 2019 Jul;48(4):266-270. doi: 10.1080/03009742.2019.1577915. Epub 2019 Apr 23.

PMID:
31012365
14.

Development and Validation of a Sensitive UHPLC-MS/MS-Based Method for the Analysis of Folylpolyglutamate Synthetase Enzymatic Activity in Peripheral Blood Mononuclear Cells: Application in Rheumatoid Arthritis and Leukemia Patients.

Muller IB, Lin M, Struys EA, Heydari P, Hebing RCF, Nurmohamed MT, van der Laken C, Lems WF, Cloos J, Jansen G, de Jonge R.

Ther Drug Monit. 2019 Oct;41(5):598-606. doi: 10.1097/FTD.0000000000000638.

PMID:
31008996
15.

Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.

Ruwaard J, Marsman AF, Nurmohamed MT, van der Horst-Bruinsma IE, Te Velthuis H, Bloem K, de Vries A, Rispens T, Wolbink G.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):756-761. Epub 2019 Mar 18.

16.

Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.

van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.

Ann Rheum Dis. 2019 May;78(5):610-616. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.

17.

Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis.

Turk SA, Heslinga M, Twisk J, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

Clin Exp Rheumatol. 2019 May-Jun;37(3):513. Epub 2019 Feb 15. No abstract available.

18.

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Layegh Z, Ruwaard J, Hebing RCF, L' Ami MJ, van der Weele W, Nurmohamed MT, Krieckaert C, Wolbink G.

Int J Rheum Dis. 2019 May;22(5):869-873. doi: 10.1111/1756-185X.13512. Epub 2019 Feb 14.

PMID:
30767391
19.

Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases.

De Lorenzis E, Gremese E, Bosello S, Nurmohamed MT, Sinagra G, Ferraccioli G.

Autoimmun Rev. 2019 Apr;18(4):317-324. doi: 10.1016/j.autrev.2019.02.002. Epub 2019 Feb 7. Review. No abstract available.

PMID:
30743079
20.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

PMID:
30700574
21.

Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.

Beek KJ, Rusman T, van der Weijden MAC, Lems WF, van Denderen JC, Konsta M, Visman I, Nurmohamed MT, van der Horst-Bruinsma IE.

J Bone Miner Res. 2019 Jun;34(6):1041-1048. doi: 10.1002/jbmr.3684. Epub 2019 Mar 25.

PMID:
30690799
22.

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.

Heslinga SC, Konings TC, van der Horst-Bruinsma IE, Kamp O, van Halm VP, de Bruin-Bon H, Peters MJ, Nurmohamed MT.

Biologics. 2018 Nov 8;12:143-149. doi: 10.2147/BTT.S176806. eCollection 2018.

23.

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.

van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE.

J Rheumatol. 2019 Feb;46(2):153-159. doi: 10.3899/jrheum.180312. Epub 2018 Nov 1.

24.

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.

Vogelzang EH, Hebing RCF, Nurmohamed MT, van Kuijk AWR, Kruijff JWF, l'Ami MJ, Krieckaert CLM, Wolbink G.

PLoS One. 2018 Oct 9;13(10):e0205125. doi: 10.1371/journal.pone.0205125. eCollection 2018.

25.

Multicentric reticulohistiocytosis: a case report.

Farokhi A, van Vugt RM, Hoekzema R, Nurmohamed MT.

BMC Res Notes. 2018 Sep 4;11(1):647. doi: 10.1186/s13104-018-3753-3.

26.

Editorial: Comorbidity Burden in Rheumatic Diseases.

Nikiphorou E, Nurmohamed MT, Szekanecz Z.

Front Med (Lausanne). 2018 Jul 3;5:197. doi: 10.3389/fmed.2018.00197. eCollection 2018. No abstract available.

27.

2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis.

Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, Duruoz T, Esbensen BA, Günther KP, Hurkmans E, Juhl CB, Kennedy N, Kiltz U, Knittle K, Nurmohamed M, Pais S, Severijns G, Swinnen TW, Pitsillidou IA, Warburton L, Yankov Z, Vliet Vlieland TPM.

Ann Rheum Dis. 2018 Sep;77(9):1251-1260. doi: 10.1136/annrheumdis-2018-213585. Epub 2018 Jul 11.

PMID:
29997112
28.

Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance.

Biesbroek PS, Heslinga SC, van de Ven PM, Peters MJL, Amier RP, Konings TC, Maroules CD, Ayers C, Joshi PH, van der Horst-Bruinsma IE, van Halm VP, van Rossum AC, Nurmohamed MT, Nijveldt R.

Clin Rheumatol. 2018 Aug;37(8):2151-2159. doi: 10.1007/s10067-018-4135-x. Epub 2018 May 12.

PMID:
29754182
29.

The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review.

Baniaamam M, Paulus WJ, Blanken AB, Nurmohamed MT.

Expert Opin Biol Ther. 2018 May;18(5):585-594. doi: 10.1080/14712598.2018.1462794. Epub 2018 Apr 23.

PMID:
29623726
30.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR; SECURE study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.

PMID:
29606564
31.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

32.

Noncanonical NF-κB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction.

Maracle CX, Agca R, Helder B, Meeuwsen JAL, Niessen HWM, Biessen EAL, de Winther MPJ, de Jager SCA, Nurmohamed MT, Tas SW.

Atherosclerosis. 2018 Mar;270:33-41. doi: 10.1016/j.atherosclerosis.2018.01.032. Epub 2018 Jan 31.

33.

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.

Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P.

Drug Saf. 2018 May;41(5):473-488. doi: 10.1007/s40264-017-0628-9. Review.

34.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. No abstract available.

PMID:
29133475
35.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

36.

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.

PMID:
28939629
37.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
38.

Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT.

Lensen KDF, van Sijl AM, Voskuyl AE, van der Laken CJ, Heymans MW, Comans EFI, Nurmohamed MT, Smulders YM, Boellaard R.

PLoS One. 2017 Aug 11;12(8):e0181847. doi: 10.1371/journal.pone.0181847. eCollection 2017.

39.

Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.

Kneepkens EL, Pouw MF, Wolbink GJ, Schaap T, Nurmohamed MT, de Vries A, Rispens T, Bloem K.

Br J Clin Pharmacol. 2017 Nov;83(11):2474-2484. doi: 10.1111/bcp.13371. Epub 2017 Aug 22.

40.

Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.

Ruwaard J, l'Ami MJ, Marsman AF, Kneepkens EL, van Denderen JC, van der Horst-Bruinsma IE, Nurmohamed MT, Wolbink G.

Scand J Rheumatol. 2018 Mar;47(2):122-126. doi: 10.1080/03009742.2017.1330419. Epub 2017 Jul 26.

PMID:
28745108
41.

Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.

Ibáñez Vodnizza SE, Nurmohamed MT, Visman IM, van Denderen JC, Lems WF, Jaime F, van der Horst-Bruinsma IE.

J Rheumatol. 2017 Sep;44(9):1355-1361. doi: 10.3899/jrheum.170094. Epub 2017 Jul 15.

PMID:
28711878
42.

Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition.

Ibáñez Vodnizza S, Visman IM, van Denderen C, Lems WF, Jaime F, Nurmohamed MT, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2017 Sep 1;56(9):1566-1572. doi: 10.1093/rheumatology/kex187.

PMID:
28605535
43.

The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis.

Agca R, Heslinga M, Kneepkens EL, van Dongen C, Nurmohamed MT.

J Rheumatol. 2017 Sep;44(9):1362-1368. doi: 10.3899/jrheum.161418. Epub 2017 Jun 1.

PMID:
28572461
44.

Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.

van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP.

Rheumatology (Oxford). 2018 Feb 1;57(2):283-290. doi: 10.1093/rheumatology/kex183.

PMID:
28541484
45.

The Relationship Between Cardiac Conduction Times, Cardiovascular Risk Factors, and Inflammation in Patients with Early Arthritis.

Turk SA, Heslinga SC, Dekker J, Britsemmer L, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

J Rheumatol. 2017 May;44(5):580-586. doi: 10.3899/jrheum.161184. Epub 2017 Apr 1.

PMID:
28365582
46.

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X.

Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.

PMID:
28363827
47.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
48.

IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis.

Damen MS, Agca R, Holewijn S, de Graaf J, Dos Santos JC, van Riel PL, Fransen J, Coenen MJ, Nurmohamed MT, Netea MG, Dinarello CA, Joosten LA, Heinhuis B, Popa CD.

Sci Rep. 2017 Jan 30;7:41629. doi: 10.1038/srep41629.

49.

Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.

Nurmohamed MT.

Nat Rev Rheumatol. 2017 Mar;13(3):136-138. doi: 10.1038/nrrheum.2017.4. Epub 2017 Jan 27. No abstract available.

PMID:
28127041
50.

Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.

l'Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ.

Clin Exp Rheumatol. 2017 May-Jun;35(3):431-437. Epub 2017 Jan 5.

PMID:
28079512

Supplemental Content

Loading ...
Support Center